Source - LSE Regulatory
RNS Number : 0242U
Deltex Medical Group PLC
20 November 2019
 

20 November, 2019

Deltex Medical Group plc
("Deltex Medical", "DEMG" or "the Group")

Finance Director Appointed

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), is pleased to announce the appointment of David Moorhouse as Group Finance Director with immediate effect.

David brings to DEMG a wide breadth of financial experience, as well as a very good understanding of the business having previously been Finance Director at the company from 1996-2001. He has been overseeing the finance function at DEMG on an interim basis since 7 October 2019. Most recently, David was Head of Finance and Administration of the International Coffee Organization from 2004 to 2017. Prior to this, he served in a number of roles including in corporate finance at European Banking Company, and as a Managing Director at an executive search firm, Russell Reynolds Associates Inc. in London and Frankfurt.

 

After graduating in Modern Languages from Queens' College, Cambridge in 1974, David started work at Kleinwort Benson Ltd, a merchant bank and subsequently qualified as a Chartered Accountant with Price Waterhouse & Co.

 

Nigel Keen, Chairman of Deltex Medical Group plc, commented:

"I am delighted that David has agreed to re-join the Board of DEMG. There is no doubt that his previous knowledge of the company along with his experience across a multitude of sectors will be invaluable to DEMG as we continue to deliver on our strategy."

 

The following information in relation to the appointment of Mr David Philip Moorhouse (aged 67) is disclosed in accordance with Schedule 2(g) of the AIM Rules for Companies.

 

Current directorships

Past directorships held within the last five years

None.

None.

 

Mr Moorhouse has an interest in 13,405 ordinary shares of 1 pence each ("Ordinary Shares") in the capital of Deltex Medical and does not hold any options over shares in the capital of the company. 

 

There is no further information to be disclosed in relation to Mr Moorhouse's appointment pursuant to AIM Rule 17 or Schedule 2(g) of the AIM rules for companies.

 

For further information, please contact:

 

Deltex Medical Group plc

01243 774 837

Nigel Keen, Chairman

investorinfo@deltexmedical.com

Andy Mears, Chief Executive

David Moorhouse, Finance Director


 

Nominated Adviser & Joint Broker


Arden Partners plc

020 7614 5900

Ciaran Walsh

Dan Gee-Summons


 

Joint Broker


Turner Pope Investments (TPI) Ltd

0203 657 0050

Andy Thacker

info@turnerpope.com

Zoe Alexander

 

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's proprietary oesophageal Doppler monitoring ("ODM") (TrueVue Doppler) measures blood flow velocity in the central circulation in real time. Minimally invasive, easy to set-up and quick to focus, the technology generates a low-frequency ultrasound signal which is highly sensitive to changes in blood flow and measures such changes in 'real time'. Deltex Medical is the only company in the enhanced haemodynamic space to have built a robust and credible evidence base demonstrating both the clinical and economic benefits of its core technology, TrueVue Doppler. This technology has been proven in a wide range of clinical trials to reduce complications suffered by patients after surgery and consequently save hospitals the costs of treating those complications.

Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor platform now provides clinicians with two further advanced haemodynamic monitoring technologies. TrueVue Impedance is an entirely non-invasive monitoring technology which transmits low magnitude, high frequency electrical signals through the thorax and measures the changes to this signal when the heart pumps blood. TrueVue PressureWave uses the peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.

 

Group goal

Haemodynamic management is now becoming widely accepted as an important part of the anaesthesia protocol for surgical patients. Consequently, the Group's focus is on maximising value from the opportunities presented, as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Group aims to provide clinicians with a single platform - a 'haemodynamic workstation' - which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's condition as well as the skill and expertise of the user. Doing this will enable the Group to partner healthcare providers to support modern haemodynamic management across the whole hospital.

The Group is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK and the USA, and through distribution arrangements in approximately 40 other countries.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RDNLIFFDLLLIFIA
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.